Property:Dosage and regime
This is a property of type Text.
F
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
First week mean number of sprays 3.7, stabilized over 4 weeks (7.4 sprays per day) +
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Week 1: dose finding; week 2-5: stable dose, max. 10 sprays
* Part A: first week average number of sprays: 3.6, second week: 6.4
* Part B: average daily number: 6.3 +
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Sativex® (nabiximol, THC 27 mg/mL, CBD 25 mg/mL) via oral spray (self-applied by patient);
week 1: dose finding; week 2-5: stable dose, max. 10 sprays
* Part A: first week average number of sprays: 3.6; second week: 6.4
* Part B: average daily number: 6.5 +
Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial +
Oral 400mg twice daily (immediately before radiotherapy and 8-12 hours after)
Start: Day 0 radiotherapy
Duration: entire radiotherapy +
Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial +
Oral 500mg twice daily (immediately before radiotherapy and 8-12 hours after)
Start: Day 0 radiotherapy
Duration: entire radiotherapy +
Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial +
Vitamin D<sub>3</sub> oil drops (color and taste matched) 4000 IU/day, for 12 weeks +
Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial +
Placebo (oil drops), for 12 weeks +
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
NA +
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
Low-carbohydrate diet with ≤20g carbohydrates per day
Supervision by dietician by telephone weekly in the first 3 months and then every 2 weeks in the last 3 months +
G
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
Oral, 400mg, 2x daily
Start: day -7 surgery
Duration: until day 28 after surgery +
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
Oral, 2x daily
Start: day -7 surgery
Duration: until day 28 after surgery +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
200 µg 1x per day, orally +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
1x per day +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
4 Zinco‐C 25‐mg tablets daily +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NA +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Median (SD) number of capsules = 3 (2-4) +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
1-4 capsules (each THC 2.5mg/CBD 2.5mg) 3x daily from one day before chemotherapy to day 5; median (SD) number of capsules: 2 (1-3) +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
3x3 tablets WOBE-MUGOS E (10mg papain, 40mg trypsin, 40mg chymotrypsin) daily, starting 3 days before the first radiotherapy treatment over a period of 54(+/-9) days until 5 days after completion of radiation therapy
+ all patients received 50 to 70 Gy telecobalt therapy using a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6-7 weeks +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
+ all patients received 50 to 70 Gy telecobalt therapy using a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6-7 weeks +
H
Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial +
All participants: pain medication, including intravenous injection of apotel 1 g, morphine sulfate 3 mg, and oral acet-aminophen 500 mg, depending on each patient’s need in the intensive care unit and ward +